MaxCyte will release its Q3 2025 financial results on November 5, 2025, followed by a conference call.
Quiver AI Summary
MaxCyte, Inc. announced that it will release its third quarter 2025 financial results on November 5, 2025, after the U.S. market closes. A conference call will be held at 4:30 p.m. Eastern Time to discuss these results, and investors can register online to participate, with early registration recommended. The call will also be available via live and archived webcast on the MaxCyte website. MaxCyte is a leader in cell engineering technologies, specializing in platforms that support the development of advanced cell therapies, including their Flow Electroporation technology and gene editing risk assessment services, which enable the creation of diverse and effective treatments for health.
Potential Positives
- MaxCyte is scheduled to release its financial results for Q3 2025, indicating transparency and communication with investors.
- The company is hosting a conference call to discuss the financial results, providing an opportunity for investor engagement and feedback.
- MaxCyte highlights its leadership in cell engineering and innovative technologies, reinforcing its position in a growing industry.
Potential Negatives
- Failure to provide financial guidance ahead of the earnings announcement may lead to uncertainty and negative investor sentiment regarding future performance.
- Dependence on market registration for conference call participation may limit investor accessibility and engagement.
- Lack of specific details regarding the anticipated financial results raises concerns about transparency and could invite skepticism among stakeholders.
FAQ
When will MaxCyte release its Q3 2025 financial results?
MaxCyte will release its Q3 2025 financial results on November 5th, 2025, after U.S. market close.
What time is the earnings conference call?
The earnings conference call will be held at 4:30 p.m. Eastern Time on November 5th, 2025.
How can I access the earnings conference call?
Investors can register online to listen to the conference call, with recommendations to register at least a day in advance.
Where can I find the archived webcast of the event?
The archived webcast will be available on the “Events” section of the MaxCyte website.
What technologies does MaxCyte specialize in?
MaxCyte specializes in cell-engineering technologies, including Flow Electroporation® and SeQure DX™ gene editing services.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MXCT Insider Trading Activity
$MXCT insiders have traded $MXCT stock on the open market 6 times in the past 6 months. Of those trades, 5 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $MXCT stock by insiders over the last 6 months:
- STANLEY C ERCK purchased 100,000 shares for an estimated $137,220
- RICHARD DOUGLAS purchased 80,000 shares for an estimated $111,039
- MAHER MASOUD (President and CEO) purchased 75,000 shares for an estimated $102,915
- DOUGLAS J SWIRSKY (CHIEF FINANCIAL OFFICER) purchased 50,000 shares for an estimated $64,500
- WILLIAM W BROOKE purchased 50,000 shares for an estimated $64,500
- REKHA HEMRAJANI sold 10,684 shares for an estimated $22,377
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MXCT Hedge Fund Activity
We have seen 63 institutional investors add shares of $MXCT stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MIRABELLA FINANCIAL SERVICES LLP added 2,900,000 shares (+78.4%) to their portfolio in Q2 2025, for an estimated $6,322,000
- BLACKROCK, INC. added 2,033,867 shares (+24.9%) to their portfolio in Q2 2025, for an estimated $4,433,830
- SWEDBANK AB removed 1,390,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,030,200
- ARROWMARK COLORADO HOLDINGS LLC removed 1,235,236 shares (-93.7%) from their portfolio in Q2 2025, for an estimated $2,692,814
- AXA S.A. added 1,215,481 shares (+123.2%) to their portfolio in Q2 2025, for an estimated $2,649,748
- MILLENNIUM MANAGEMENT LLC removed 1,215,179 shares (-88.2%) from their portfolio in Q2 2025, for an estimated $2,649,090
- CADIAN CAPITAL MANAGEMENT, LP removed 1,113,251 shares (-11.1%) from their portfolio in Q2 2025, for an estimated $2,426,887
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MXCT Analyst Ratings
Wall Street analysts have issued reports on $MXCT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stephens & Co. issued a "Overweight" rating on 07/22/2025
To track analyst ratings and price targets for $MXCT, check out Quiver Quantitative's $MXCT forecast page.
Full Release
ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the third quarter 2025 after the U.S. market close on Wednesday, November 5 th , 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are required to
register online
. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at
https://investors.maxcyte.com/
.
About MaxCyte
At MaxCyte
®
, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation
®
technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at
maxcyte.com
and follow us on
X
and
LinkedIn
.
Investor Relations
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
[email protected]
Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
[email protected]
